# TACE Plus HAIC Combined With Regorafenib for Liver Metastasis of Colorectal Cancer Refractory to Standard Treatment Regimens

> **NCT06071052** · PHASE2 · COMPLETED · sponsor: **First Affiliated Hospital, Sun Yat-Sen University** · enrollment: 21 (actual)

## Conditions studied

- Liver Metastasis Colon Cancer

## Interventions

- **COMBINATION_PRODUCT:** TACE and HAIC Combined With Regorafenib

## Key facts

- **NCT ID:** NCT06071052
- **Lead sponsor:** First Affiliated Hospital, Sun Yat-Sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-12-01
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2026-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06071052

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06071052, "TACE Plus HAIC Combined With Regorafenib for Liver Metastasis of Colorectal Cancer Refractory to Standard Treatment Regimens". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06071052. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*